Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer.
Schamhart
D H
DH
Department of Urology, University of Amsterdam, The Netherlands.
De Boer
E C
EC
Vleeming
R
R
Kurth
K H
KH
D000327:Adsorption; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005057:Eukaryotic Cells / Q000382:microbiology; D006025:Glycosaminoglycans / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D009163:Mycobacterium bovis / Q000276:immunology; D011509:Proteoglycans / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000628:therapy*
D001500:BCG Vaccine; D006025:Glycosaminoglycans; D011509:Proteoglycans